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Abstract: Up to 90% of patients with tuberous sclerosis complex (TSC) have epilepsy, and
in over half of patients seizure control cannot be achieved by regular antiepileptic drugs. The
underlying problem is mTOR hyperactivation due to loss of function of the TSC proteins.
Treatment with everolimus, an mTOR inhibitor, has been shown to be of great beneﬁt to TSC
patients, both in reducing tumor growth and as a treatment for intractable epilepsy. Up to
40% of TSC patients with intractable epilepsy show a clinically relevant seizure response to
everolimus. It has not yet fully lived up to its promise as a disease-modifying drug, however,
as half of TSC patients with intractable epilepsy do not show a clinically relevant seizure
frequency reduction. There is no evidence yet of a positive effect on the cognitive and
neuropsychiatric deﬁcits in TSC patients. In preclinical studies, mTOR inhibition can rescue
abnormal neuronal migration and synapse formation that is caused by mTOR hyperactiva-
tion. These studies show a critical time window that suggests that mTOR inhibition may be
most beneﬁcial in young children. The trials done so far have not studied treatment in
children under 2 years of age, although case series suggest that the safety proﬁle is similar to
that in older children. Further studies into the optimal time window, dosing schedules and
possibly combination with other drugs may further improve the beneﬁt of everolimus for
TSC patients.
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Tuberous sclerosis complex
Tuberous Sclerosis complex (TSC) is a rare autosomal dominant disorder that is
characterized by the development of multiple hamartomas. These are typically seen
in brain, kidney, skin, heart, liver and lungs, although other organs can be affected.
There is a large variability in the severity of TSC between patients; however, the
neurological and psychiatric features are often the most important clinical pro-
blems. These include intellectual disability, autism, anxiety and attention problems,
summarized in the term TSC–Associated–Neuropsychiatric–Disorders (TAND), but
epilepsy is often the most important determinant of quality of life.1 Up to 90% of
TSC patients develop epilepsy, and over half of the patients with TSC and epilepsy
have seizures refractory to anti-epileptic drugs.
Hyperactivation of the mTOR (mechanistic target of rapamycin) pathway due to
loss of function of the TSC proteins is thought to be the cause of both the focal
cortical dysplasia and the intractable epilepsy in TSC. Hyperactivation of mTOR in
neuronal precursors during prenatal brain development leads to abnormal migration
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and differentiation of affected neurons, resulting in giant
cells, dysmorphic neurons, abnormal lamination and inter-
rupted migration. Clusters of these abnormal neurons can be
seen on magnetic resonance imaging (MRI) imaging as
tubers and radial migration lines. During further brain
development, mTOR hyperactivation disturbs neuronal
arborization and spine maturation. TSC patients with germ-
line mutations are haploinsufﬁcient for either the TSC1 or
TSC2 gene in all their cells. Second hit mutations result in
extreme mTOR hyperactivation and are implicated in the
development of benign tumors associated with TSC. The
giant cells in the tubers are also affected by a second hit.
Treatment of epilepsy with mTOR
inhibitors
Historically, epilepsy in the context of TSC was treated as
any other focal epilepsy following the ILAE (International
League against epilepsy) guidelines. The elucidation of the
function of the TSC1 and TSC2 genes, and availability of
mTOR inhibitors, quickly led to hope for a treatment
directly aimed at the underlying dysfunction of the
affected cells. For epilepsy, this implied a treatment direc-
ted at epileptogenesis, instead of symptomatic treatment of
seizures, and possibly treatment with a disease-modifying
drug. Everolimus and sirolimus, both mTOR-inhibiting
drugs, were shown to be effective in the treatment of TSC-
related renal angiomyolipoma and subependymal giant cell
astrocytoma in clinical trials.2,3 Preclinical research in
animals models seemed to support the hypothesis that
mTOR inhition could also rescue epilepsy.4,5 Several stu-
dies in TSC patients showed a reduction in seizure fre-
quency due to mTOR inhibition.6,7 The EXIST-3 trial
included 366 patients and showed a 50% seizure reduction
response rate of 15% with placebo compared with 28% for
low-exposure everolimus and 40% for high-exposure
everolimus.8 This was highly signiﬁcant, and led to the
registration of everolimus for the treatment of intractable
epilepsy in patients with TSC aged 2 years and older.
Current place of mTOR inhibitors in
the treatment of TSC related
epilepsy
The results of the EXIST-3 trial and the registration of
everolimus for the treatment of intractable seizures in TSC
have changed the current treatment recommendations
(Table 1). In the EXIST-3 trial, patients aged 2 years and
older were included, so everolimus cannot yet be
recommended for younger patients. As level 1 evidence
is only available for the efﬁcacy of everolimus in patients
that failed at least 2 anti-epileptic drugs, everolimus is not
recommended as a ﬁrst- or second-line treatment. In the
EXIST-3 trial, the seizure response was better in patients
with a higher everolimus exposure, indicating a dose–
response relationship. The current dosing recommenda-
tions are to aim for a trough level within the range of
5–7 ng/mL initially and 5–15 ng/mL in the event of an
inadequate clinical response.9
Safety proﬁle of mTOR inhibitors
The most important side effects of mTOR inhibitors are
(apthous) stomatitis and respiratory infections. A recent
meta-analysis of safety data showed a high risk of stoma-
titis (RR 3.20) in patients who received mTOR inhibitors.
The incidence of upper respiratory tract infections was
high in both treated and untreated patients with a similar
risk (RR 1.08).7 Treatment-related deaths due to pneumo-
nia or septic shock have been reported.12 Recently the
extension data for the EXIST-3 registration study were
published showing that of 366 participants, 81% remained
on everolimus at 1 year of follow-up and 74% at 2 years.
13% discontinued because of adverse events.12 This shows
that the side effect proﬁle is acceptable for the majority of
patients. At the 1-year follow-up mark, 47% of the patients
taking everolimus had a seizure response of >50%, which
is considered clinically relevant. For those patients with
limited seizure response, the advantages of everolimus
may not outweigh the side effects. On the other hand,
mTOR inhibition can also beneﬁt TSC-related symptoms
in other organs, such as facial angioﬁbroma, pulmonary
lymphangioleimyomatosis and renal angiomyolipoma.
Questions remaining to be
answered
Does everolimus suppress seizures or
prevent epilepsy? What does that mean
for the optimal treatment timing?
An important question remaining is whether everolimus
works as an antiseizure medication or antiepileptogenic
agent, or as both. If epilepsy is mainly the result of the
focal cortical dysplasia that formed during the prenatal
phase of neuronal migration and differentiation, then it
may be that the epileptogenic process has already been
started prenatally, and epilepsy may be inevitable. In TSC
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patients, the epileptic focus is often associated with a tuber
and removal of such a tuber and the perituberal tissue by
epilepsy surgery has a high chance of inducing seizure
remission. This may support the hypothesis that the cor-
tical dysplasia is central in epileptogenesis.
However, if dynamic mTOR-dependent processes dur-
ing development are the main driver of epileptogenesis,
inhibition of mTOR hyperactivation may prevent epilepto-
genesis. Arguments for the latter originate from animal
models where acute mTOR hyperactivation in the absence
of cortical dysplasia can trigger epilepsy.4 In these mice,
epilepsy onset can be prevented by rapamycin. Another
Tsc1 animal model shows that there are multiple time
windows where mTOR inhibition may work to prevent
abnormal brain development.13 In these mouse embryos,
TSC was induced at different times of brain development.
During the prenatal neuronal migration period, rapamycin
treatment improved malpositioning of neurons. When
administered early postnatally (P1-P13), aberrant arboriza-
tion of affected neurons was improved and in a later period
(P15-P27) spine maturation was partly rescued. After the
critical time window for these processes, these abnormal-
ities cannot be rescued by mTOR inhibition. It is yet
unclear how to translate these ﬁndings to TSC patients,
but we know that much of brain maturation and network
formation takes place after birth. In humans, neuronal
migration takes place before birth, but synaptogenesis
continues until approximately 3.5 years of age. This sug-
gests that there may be a (partial) treatment window in
humans postnatally. A possible biomarker for the quality
of network development is MRI imaging of the white
matter using diffusion techniques. Many TSC patients
show abnormal white matter integrity, and MRI data
from the NCT00411619-trial of everolimus for subepen-
dymal giant cell astrocytoma showed that the development
of white matter integrity was improved by mTOR inhibi-
tion in patients with TSC.14 The conclusive evidence is
still out, but it seems likely that mTOR inhibition can have
antiepileptogenic effects in a subset of TSC patients. It is
likely that this subset will be largely deﬁned by age, and
we will need to further study the effect of mTOR inhibi-
tion in children under 2 years old as a symptomatic and
preventative treatment. Small case series suggest that tem-
porary treatment with mTOR inhibition in infants is prob-
ably safe showing a similar adverse events proﬁle as in
older children.15,16 However, age-speciﬁc concerns regard-
ing vaccinations and the higher burden of infectious dis-
ease in young children cannot yet be fully addressed.Ta
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Interestingly, a report of a case series of 4 infants with
TSC-related refractory West syndrome treated with ever-
olimus reported seizure freedom in 2 of 4.17
Early or preventative treatment trials should therefore
also address the question of treatment duration. Treatment
may not be necessary long term for the prevention of epi-
leptogenesis, and potential long-term side effects on growth
or immunity in young children are largely unknown. These
cannot be fully investigated in controlled trials that normally
last a maximum of a few years, but prospective cohort
studies will hopefully answer these questions.
Can everolimus prevent intellectual
disability and autism in TSC?
The age of onset of seizures and the time to response to
treatment are the most important predictors of cognitive
development in children with TSC.18–20 Also, the age of
seizure onset and severity of autistic features are closely
interrelated, suggesting that early and aggressive treatment
of seizures can ameliorate other neurocognitive outcomes.21
The recommended treatment at this time for young children
with TSC and focal seizures or infantile spasms is
vigabatrin.10 Treatment with vigabatrin soon after seizure
onset in infants results in signiﬁcantly lower risks of intellec-
tual disability and autism, as compared to children treated
with a treatment delay.20 Treatment with vigabatrin before
the onset of seizures may be even more beneﬁcial, and the
running EPISTOP and PREVENT studies will hopefully
answer this important question.19 Since epilepsy is such an
important driver of intellectual disability and autism in chil-
dren with TSC, experts agree that aggressive treatment of
early onset epilepsy is warranted.10 For now, it is uncertain
whether preseizure onset treatment with mTOR inhibition
could prevent the development of epilepsy and contribute to
better cognitive development through this mechanism.
A positive effect of 6 months mTOR inhibition on neurocog-
nition and behavior in children with TSC of 6 years and
oldercould not be shown.22 There is currently no support
for prescribing everolimus to improve behavior or cognition
in the absence of intractable epilepsy.
Will a combination of everolimus with
other disease-modifying drugs be of
additional beneﬁt?
When mTOR inhibition is discussed in the context of
treatment of TSC, this usually refers to mTORC1 inhibi-
tion speciﬁcally. There are, however, other targets and
functions of the TSC proteins that may be affected by
mutations in TSC1 or TSC2 and may contribute to the
phenotype. For example, TSC1 functions independently
of TSC2 by regulating TGF-β-induced growth arrest and
epithelial-to-mesenchymal transition (EMT).23 Loss of
function of the TSC proteins also affects mTORC2 and
AKT activity. The contribution of these cellular processes
to the phenotype of TSC patients is not clear, but further
elucidation may reveal other potential treatment targets.
Conclusion
Everolimus has been shown to be of great beneﬁt to TSC
patients, both in reducing tumor growth and as a treatment for
intractable epilepsy. It has not fully lived up to its promise as
a disease-modifying drug, however. At least half of TSC
patients with intractable epilepsy do not show a clinically rele-
vant seizure frequency reduction. There is no evidence yet of
a positive effect on the cognitive and neuropsychiatric deﬁcits
in TSC patients. Further studies into the optimal time window,
dosing schedules and possibly combination with other drugs
may improve the beneﬁt of everolimus for TSC patients.
Disclosure
Dr. van Eeghen has provided consultation on an advisory
board for Novartis. Dr. de Wit has provided consultation
on advisory boards for Novartis and Hoffmann-La Roche.
Compensation was paid to Dr. de Wit's institution, the
Erasmus MC. The authors report no other conﬂicts of
interest in this work.
References
1. Tritton T, Bennett B, Brohan E, et al. Health utilities and quality of life
in individuals with tuberous sclerosis complex (TSC) who experience
epileptic seizures: a web-based survey. Epilepsy Behav.
2019;92:213–220. doi:10.1016/j.yebeh.2018.11.021
2. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for
angiomyolipoma associated with tuberous sclerosis complex or spora-
dic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised,
double-blind, placebo-controlled trial. Lancet. 2013;381
(9869):817–824. doi:10.1016/S0140-6736(12)61767-X
3. Franz DN, Agricola K, Mays MA, et al. Everolimus for subependymal
giant cell astrocytoma: 5-year ﬁnal analysis. Ann Neurol. 2015;78
(6):929–938. doi:10.1002/ana.24523
4. Abs E, Goorden SM, Schreiber J, et al. TORC1-dependent epilepsy
caused by acute biallelic Tsc1 deletion in adult mice. Ann Neurol.
2013;74(4):569–579. doi:10.1002/ana.23943
5. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy
in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63
(4):444–453. doi:10.1002/ana.21331
6. Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for
epilepsy in children with tuberous sclerosis complex: a randomized
controlled trial. Neurology. 2016;87(10):1011–1018. doi:10.1212/
WNL.0000000000003077
Overwater et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Therapeutics and Clinical Risk Management 2019:15954
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
17
6.
8 
on
 2
2-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
7. Li M, Zhou Y, Chen C, et al. Efﬁcacy and safety of mTOR inhibitors
(rapamycin and its analogues) for tuberous sclerosis complex: a
meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi:10.1186/
s13023-019-1012-x
8. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus
therapy for treatment-resistant focal-onset seizures associated with
tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind,
placebo-controlled study. Lancet. 2016;388(10056):2153–2163.
doi:10.1016/S0140-6736(16)31419-2
9. Franz DN, Lawson JA, Yapici Z, et al. Everolimus dosing recom-
mendations for tuberous sclerosis complex-associated refractory
seizures. Epilepsia. 2018;59(6):1188–1197. doi:10.1111/epi.14085
10. Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy
associated with tuberous sclerosis complex: updated clinical
recommendations. Eur J Paediatr Neurol. 2018;22(5):738–748.
doi:10.1016/j.ejpn.2018.05.006
11. Curatolo P, Jóźwiak SNabbout R. TSC consensus meeting forSEGA
and epilepsy management. management of epilepsy associated with
tuberous sclerosis complex (TSC): clinicalrecommendations. Eur J
Paediatr Neurol. 2012;16(6): doi:10.1016/j.ejpn.2012.05.004
12. Franz DN, Lawson JA, Yapici Z, et al. Everolimus for
treatment-refractory seizures in TSC: extension of a randomized con-
trolled trial. Neurol Clin Pract. 2018;8(5):412–420. doi:10.1212/
CPJ.0000000000000514
13. Cox RL, Calderon de Anda F, Mangoubi T, Yoshii A. Multiple
critical periods for rapamycin treatment to correct structural defects
in Tsc-1-suppressed brain. Front Mol Neurosci. 2018;11:409.
doi:10.3389/fnmol.2018.00409
14. Peters JM, Prohl A, Kapur K, et al. Longitudinal effects of everolimus
on white matter diffusion in tuberous sclerosis complex. Pediatr Neurol.
2019;90:24–30. doi:10.1016/j.pediatrneurol.2018.10.005
15. Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N.
Accelerated cardiac rhabdomyoma regression with everolimus in
infants with tuberous sclerosis complex. Pediatr Cardiol. 2017;38
(2):394–400. doi:10.1007/s00246-016-1528-y
16. Krueger DA, Capal JK, Curatolo P, et al. TSCure research group.
Short-term safety of mTOR inhibitors in infants and very young
children with tuberous sclerosis complex (TSC): multicentre clinical
experience. Eur J Paediatr Neurol. 2018;22(6):1066–1073.
doi:10.1016/j.ejpn.2018.06.007
17. Samueli S, Dressler A, Gröppel G, Scholl T, Feucht M. Everolimus in
infants with tuberous sclerosis complex-related West syndrome: ﬁrst
results from a single-center prospective observational study.
Epilepsia. 2018;59(9):e142–e146. doi:10.1111/epi.14529
18. Overwater IE, Verhaar BJ, Lingsma HF, et al. Interdependence of
clinical factors predicting cognition in children with tuberous sclero-
sis complex. J Neurol. 2017;264(1):161–167. doi:10.1007/s00415-
016-8335-5
19. Jóźwiak S, Kotulska K, Domańiska-Pakiela D, et al. Antiepileptic
treatment before the onset of seizures reduces epilepsy severity and
risk of mental retardation in infants with tuberous sclerosis complex.
Eur J Paediatr Neurol. 2011;15:424–431. doi:10.1016/j.ejpn.2011.
03.010
20. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early
control of seizures improves long-term outcome in children with
tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14
(2):146–149. doi:10.1016/j.ejpn.2009.03.003
21. van Eeghen AM, Pulsifer MB, Merker VL, et al. Understanding
relationships between autism, intelligence, and epilepsy: a
cross-disorder approach. Dev Med Child Neurol. 2013;55
(2):146–153. doi:10.1111/dmcn.12044
22. Krueger DA, Sadhwani A, Byars AW, et al. Everolimus for treat-
ment of tuberous sclerosis complex-associated neuropsychiatric
disorders. Ann Clin Transl Neurol. 2017;4(12):877–887. doi:10.10
02/acn3.494
23. Thien A, Prentzell MT, Holzwarth B, et al. TSC1 activates TGF-
β-Smad2/3 signaling in growth arrest and epithelial-to-
mesenchymal transition. Dev Cell. 2015;32(5):617–630.
doi:10.1016/j.devcel.2015.01.026
Therapeutics and Clinical Risk Management Dovepress
Publish your work in this journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing
on concise rapid reporting of clinical studies in all therapeutic areas,
outcomes, safety, and programs for the effective, safe, and sustained
use of medicines. This journal is indexed on PubMed Central, CAS,
EMBase, Scopus and the Elsevier Bibliographic databases. The
manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use.
Visit http://www.dovepress.com/testimonials.php to read real quotes
from published authors.
Submit your manuscript here: https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Dovepress Overwater et al
Therapeutics and Clinical Risk Management 2019:15 submit your manuscript | www.dovepress.com
DovePress
955
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
17
6.
8 
on
 2
2-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
